Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Aaqib Sohail, Jonathan Hacker, Tessa Ryan, Alanna McGill, Regan Bergmark, Neil Bhattacharyya, Stella E Lee, Alice Maxfield, Rachel Roditi, Amélie M Julé, Alec Griffith, James Lederer, Tanya M Laidlaw, Kathleen M Buchheit
BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) causes nasal obstruction and olfactory dysfunction. Aspirin-exacerbated respiratory disease (AERD) is the triad of CRSwNP, asthma, and respiratory reactions to COX-1 inhibitors. Patients with AERD have elevated nasal IL-5 levels and high numbers of antibody-secreting cells (ASCs), including plasma cells and plasmablasts, in their polyp tissue; in addition, their nasal polyp (NP) IgE levels are correlated with disease severity and recurrence of nasal polyposis...
February 2024: Journal of Allergy and Clinical Immunology
#22
JOURNAL ARTICLE
Dinah Foer, Taneem Amin, Jun Nagai, Yumi Tani, Chunli Feng, Tao Liu, Dawn C Newcomb, Juying Lai, Hiroaki Hayashi, William E Snyder, Alanna McGill, Anabel Lin, Tanya M Laidlaw, Kevin D Niswender, Joshua A Boyce, Katherine N Cahill
Platelets are key contributors to allergic asthma and aspirin-exacerbated respiratory disease (AERD), an asthma phenotype involving platelet activation and IL-33-dependent mast cell activation. Human platelets express the glucagon-like peptide-1 receptor (GLP-1R). GLP-1R agonists decrease lung IL-33 release and airway hyperresponsiveness in mouse asthma models. We hypothesized that GLP-1R agonists reduce platelet activation and downstream platelet-mediated airway inflammation in AERD. GLP-1R expression on murine platelets was assessed using flow cytometry...
December 15, 2023: Journal of Immunology
#23
REVIEW
Erin K O'Brien, Elina Jerschow, Rohit D Divekar
Aspirin-exacerbated respiratory disease (AERD) is a subtype of chronic rhinosinusitis with polyps (CRSwNP) and asthma with higher recurrence of nasal polyps after surgery and severe asthma. Patients with CRSwNP and asthma should be screened for AERD by detailed history of aspirin/nonsteroidal anti-inflammatory drug reactions and review of medications that may mask aspirin reaction or directly by aspirin challenge. Treatment of AERD may require more intensive therapy, including endoscopic sinus surgery, daily aspirin therapy, leukotriene modifiers, or biologics...
October 11, 2023: Otolaryngologic Clinics of North America
#24
JOURNAL ARTICLE
Eun-Kyung Kwon, Tae-Wook Kang, Taeyun Oh, Oak-Sung Choo, Young-Min Ye, Hae-Sim Park, Ga-Young Ban
Dysregulation of the arachidonic acid metabolic pathway is the most widely known pathomechanism of aspirin-exacerbated respiratory disease (AERD). This study aimed to perform integrative analysis of transcriptomic and epigenomic profiling with network analysis to determine the novel pathogenic features of AERD. Ten patients with asthma including 5 patients with AERD and another 5 patients with aspirin tolerant asthma (ATA) were enrolled. Nasal scraping was performed and nasal mucosa was used in omics profiling...
September 2023: Allergy, Asthma & Immunology Research
#25
REVIEW
Lynn Manhaeghe, Anna-Magdalena Goethals, Nathalie Van Aerde, Pascal Frederiks, Peter Sinnaeve, Stefan Janssens, Rik Willems
Takotsubo syndrome (TTS) is a transient left ventricle dysfunction usually caused by a stressful trigger (emotional or physical). We report the case of a 77 year-old female patient who presented with TTS caused by a pheochromocytoma, a catecholamine-producing neuroendocrine tumour. Diagnosis was facilitated by acute kidney injury prompting renal ultrasound, recurrence of TTS and symptoms of episodic palpitations, profuse sweating and labile blood pressure. Furthermore, during her hospitalisation the patient also developed an Ogilvie syndrome, an acute colonic pseudo-obstruction, due to the catecholamine-excess...
October 12, 2023: Acta Cardiologica
#26
JOURNAL ARTICLE
Emily Gansert, Dan Morgenstern-Kaplan, Angela M Donaldson, Matthew A Rank, Alexei Gonzalez-Estrada
BACKGROUND: Current aspirin desensitization protocols for aspirin-exacerbated respiratory disease (AERD) require from 1 to 3 days to complete. OBJECTIVE: Our aim was to assess the implementation of a 1-day versus 2-day aspirin desensitization protocol in patients with aspirin-exacerbated respiratory disease. METHODS: We used a preintervention-postintervention quality improvement design to compare the completion rates, reaction rates, and estimated costs of a 2-day versus 1-day aspirin desensitization...
November 2023: J Allergy Clin Immunol Glob
#27
REVIEW
Tanya M Laidlaw, Andrew A White
No abstract text is available yet for this article.
September 29, 2023: Journal of Allergy and Clinical Immunology in Practice
#28
REVIEW
Diego M Conti, Eduardo J Correa, Glenis K Scadding
INTRODUCTION: Aspirin desensitization (AD) and aspirin therapy after desensitization (ATAD) are therapeutic interventions for patients with aspirin-exacerbated respiratory disease (AERD). Our aim is to investigate whether its addition to endoscopic sinus surgery (ESS) improves the overall prognosis of the disease. METHODS: A systematic review of the current literature including adult patients with a positive diagnosis of AERD undergoing endoscopic sinus surgery (ESS) in the context or in absence of upper airway comorbidity, prior to AD + ATAD...
2023: Front Allergy
#29
Krista M Shaw, Brittanie I Neaves, Hayden A Springer, Christopher A Coop
Kounis syndrome is angina or acute coronary syndrome caused by mast cell degranulation and inflammatory cell activation. We present a case of a patient with underlying aspirin-exacerbated respiratory disease (AERD) and previous anaphylaxis to aspirin. The patient underwent aspirin desensitization and was then treated with high-dose aspirin. Unfortunately, he developed recurrent angina and myocardial infarction (MI). Numerous left heart catheterizations revealed vasospasms as the etiology of his MIs; however, therapy with increasing doses of vasodilators yielded no improvement in the patient's condition...
September 2023: Curēus
#30
REVIEW
So Lim Kim, Matthew A Rank, Anju Tripathi Peters
The Allergy-Immunology Joint Task Force on Practice Parameters has published the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) guidelines for the medical management of chronic rhinosinusitis with nasal polyposis (CRSwNP). The practice parameter provides evidence-based guidelines on the use of intranasal corticosteroids (INCS) and biologics for CRSwNP, and aspirin therapy after desensitization (ATAD) for the management of aspirin-exacerbated respiratory disease (AERD). Evidence on surgery was not assessed...
September 2023: Annals of Allergy, Asthma & Immunology
#31
JOURNAL ARTICLE
Alma Helevä, Aada Murtomäki, Heini Huhtala, Jean Bousquet, Annika Luukkainen, Jussi Karjalainen, Riikka Lemmetyinen, Jari Haukka, Paulus Torkki, Mikko Nuutinen, Sanna Toppila-Salmi
BACKGROUND: Asthma with NSAID-exacerbated respiratory disease (NERD) is associated with uncontrolled or severe asthma. NERD patients are more prone to severe allergic reactions and their asthma exacerbations lead to hospitalisations twice as often compared to patients with non-NERD-asthma. NERD patients are prone to recurrent nasal polyposis requiring frequent endoscopic sinus surgeries. However, the early risk factors of NERD are not fully understood. The aim was to identify risk factors of NERD among patients with adult-onset asthma...
August 2023: Clinical and Translational Allergy
#32
REVIEW
Austin Heffernan, Amir Shafiee, Teffran Chan, Sydney Sparanese, Andrew Thamboo
OBJECTIVE: The aim was to discuss the role of non-type 2 inflammation in patients diagnosed with chronic rhinosinusitis (CRS) and comorbid lower airway disease. DATA SOURCES: Medline, Embase, National Institute for Health and Care Excellence, TRIP Database, ProQuest, Clinicaltrials.gov, Cochrane Central Registry of Controlled Trials, Web of Science, government and health organizations, and graduate-level theses. REVIEW METHODS: This scoping review followed PRISMA-ScR guidelines...
August 24, 2023: Laryngoscope
#33
JOURNAL ARTICLE
Geoffrey Chupp, Isam Alobid, Njira L Lugogo, Harsha H Kariyawasam, Arnaud Bourdin, Adam M Chaker, Steven G Smith, Ana R Sousa, Bhabita Mayer, Robert H Chan, Andrea Matucci
BACKGROUND: Systemic corticosteroids (SCS) are associated with short- and long-term adverse effects. OBJECTIVE: To assess mepolizumab efficacy according to prior SCS use and characterize mepolizumab's SCS-sparing capabilities, in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP). METHODS: In the randomized, double-blind, Phase III SYNAPSE trial (NCT03085797), adults with severe CRSwNP eligible for repeat sinus surgery despite standard of care treatment received mepolizumab (100 mg subcutaneously) or placebo every 4 weeks for 52 weeks...
August 14, 2023: Journal of Allergy and Clinical Immunology in Practice
#34
JOURNAL ARTICLE
Hyun-Seob Jeon, Jae-Hyuk Jang, Youngsoo Lee, Hae-Sim Park
BACKGROUND: Aspirin-exacerbated respiratory disease (AERD) and IgG4-related disease (IgG4RD) share a common pathway of Th2-mediated immune mechanism; there have been several cases of IgG4RD developed in patients with asthma, especially in those comorbid with chronic rhinosinusitis (CRS). IgG4RD has often been treated with systemic corticosteroids, rituximab, or immune-suppressive agents, but frequently failed with relapse. CASE PRESENTATION: Here, we present a case of a 64-year-old male patient with severe AERD with CRS complicated with IgG4RD, who has been successfully treated and maintained with anti-IL-4 receptor antibody, dupilumab after achieving unsatisfactory responses with previous treatments including steroids, rituximab, omalizumab, and reslizumab...
August 5, 2023: Allergy, Asthma, and Clinical Immunology
#35
JOURNAL ARTICLE
Jana H Badrani, Kellen Cavagnero, Jacqueline J Eastman, Alex S Kim, Allyssa Strohm, Carol Yan, Adam Deconde, Bruce L Zuraw, Andrew A White, Sandra C Christiansen, Taylor A Doherty
BACKGROUND: Aspirin exacerbated respiratory disease (AERD) is associated with high levels of cysteinyl leukotrienes, prostaglandin D2 (PGD2), and low levels of prostaglandin E2 (PGE2). Further, 15-hydroxyeicosatetraenoic acid (15-HETE) levels may have predictive value in aspirin desensitization therapeutic outcomes. Accumulation of nasal group 2 innate lymphoid cells (ILC2s) has been demonstrated during COX-1 inhibition in AERD though the relationships between tissue ILC2 accumulation, reaction symptom severity, and novel lipid biomarkers is unknown...
August 3, 2023: Journal of Allergy and Clinical Immunology
#36
JOURNAL ARTICLE
Kelley Nicole Dages, Olufemi Sofola-James, Esha Sehanobish, Prudhvi Regula, Chien-Chang Chen, Sergio Elias Chiarella, Rohit Dilip Divekar, Hillel W Cohen, Elina Jerschow
BACKGROUND: Nonsteroidal anti-inflammatory drugs-exacerbated respiratory disease (N-ERD) has a triad of symptoms: nasal polyposis, asthma, and NSAID hypersensitivity. Little is known about symptom timing and disease progression. OBJECTIVE: The aim of this study is to characterize disease progression in N-ERD. METHODS: Patients with N-ERD were prospectively interviewed and classified into four groups based on their first symptom at initial N-ERD onset (asthma, nasal polyps, NSAID hypersensitivity, or all concurrently)...
August 2, 2023: Journal of Allergy and Clinical Immunology in Practice
#37
JOURNAL ARTICLE
Emily Garvey, Bita Naimi, Alexander Duffy, Paavali Hannikainen, Chase Kahn, Douglas Farquhar, Marc Rosen, Mindy Rabinowitz, Elina Toskala, Gurston Nyquist
INTRODUCTION: Chronic rhinosinusitis with nasal polyposis (CRSwNP) is often treated with endoscopic sinus surgery (ESS); however, patients may require revision surgery due to recurrence. To date, no studies have compared outcomes for combined surgery and biologic therapy for CRSwNP compared with biologic therapy alone. METHODS: Retrospective case-control study of CRSwNP patients who underwent ESS while on dupilumab or mepolizumab (ESS-biologic cohort) compared with CRSwNP patients on biologic therapy (biologic-only controls)...
July 28, 2023: International Forum of Allergy & Rhinology
#38
JOURNAL ARTICLE
Eosinophilic Granulomatosis with Polyangiitis Presenting as Aspirin Exacerbated Respiratory Disease.
Sabrina D Herzberg, Alyssa M Bosso, Neel R Sangal, John V Bosso
No abstract text is available yet for this article.
July 22, 2023: Annals of Allergy, Asthma & Immunology
#39
JOURNAL ARTICLE
Michael J Adame, Mukaila Raji, Yong Shan, Yuanyi Zhang, Yong-Fang Kuo, Julia W Tripple
BACKGROUND: Aspirin exacerbated respiratory disease (AERD) consists of chronic rhinosinusitis with nasal polyps (CRSwNP), asthma, and hypersensitivity to aspirin or non-steroidal anti-inflammatory drugs (NSAIDs). Asthma is associated with increased risk of atherosclerotic cardiovascular diseases (ASCVD). However, there is lack of data on association between AERD and ASCVD. OBJECTIVE: To investigate the relationship between AERD and subsequent risk of ASCVD. METHODS: An algorithm to find patients with AERD was generated and validated through chart review at our home institution...
July 17, 2023: Journal of Allergy and Clinical Immunology in Practice
#40
JOURNAL ARTICLE
Maria Elena Maccari, Martin Wolkewitz, Charlotte Schwab, Tiziana Lorenzini, Jennifer W Leiding, Nathalie Aladjdi, Hassan Abolhassani, Wadih Abou-Chahla, Alessandro Aiuti, Saba Azarnoush, Safa Baris, Vincent Barlogis, Federica Barzaghi, Ulrich Baumann, Marketa Bloomfield, Nadezda Bohynikova, Damien Bodet, David Boutboul, Giorgia Bucciol, Matthew S Buckland, Siobhan O Burns, Caterina Cancrini, Pascal Cathébras, Marina Cavazzana, Morgane Cheminant, Matteo Chinello, Peter Ciznar, Tanya I Coulter, Maud D'Aveni, Olov Ekwall, Zelimir Eric, Efrem Eren, Anders Fasth, Pierre Frange, Benjamin Fournier, Marina Garcia-Prat, Martine Gardembas, Christoph Geier, Sujal Ghosh, Vera Goda, Lennart Hammarström, Fabian Hauck, Maximilian Heeg, Edyta Heropolitanska-Pliszka, Anna Hilfanova, Stephen Jolles, Elif Karakoc-Aydiner, Gerhard R Kindle, Ayca Kiykim, Christian Klemann, Patra Koletsi, Sylwia Koltan, Irina Kondratenko, Julia Körholz, Renate Krüger, Eric Jeziorski, Romain Levy, Guillaume Le Guenno, Guillaume Lefevre, Vassilios Lougaris, Antonio Marzollo, Nizar Mahlaoui, Marion Malphettes, Andrea Meinhardt, Etienne Merlin, Isabelle Meyts, Tomas Milota, Fernando Moreira, Despina Moshous, Anna Mukhina, Olaf Neth, Jennifer Neubert, Benedicte Neven, Alexandra Nieters, Raphaele Nove-Josserand, Eric Oksenhendler, Ahmet Ozen, Peter Olbrich, Antoinette Perlat, Malgorzata Pac, Jana Pachlopnik Schmid, Lucia Pacillo, Alba Parra-Martinez, Olga Paschenko, Isabelle Pellier, Asena Pinar Sefer, Alessandro Plebani, Dominique Plantaz, Seraina Prader, Loic Raffray, Henrike Ritterbusch, Jacques G Riviere, Beatrice Rivalta, Stephan Rusch, Inga Sakovich, Sinisa Savic, Raphael Scheible, Nicolas Schleinitz, Catharina Schuetz, Ansgar Schulz, Anna Sediva, Michaela Semeraro, Svetlana O Sharapova, Anna Shcherbina, Mary A Slatter, Georgios Sogkas, Pere Soler-Palacin, Carsten Speckmann, Jean-Louis Stephan, Felipe Suarez, Alberto Tommasini, Johannes Trück, Annette Uhlmann, Koen J van Aerde, Joris van Montfrans, Horst von Bernuth, Klaus Warnatz, Tony Williams, Austen J J Worth, Winnie Ip, Capucine Picard, Emilie Catherinot, Zohreh Nademi, Bodo Grimbacher, Lisa R Forbes Satter, Sven Kracker, Anita Chandra, Alison M Condliffe, Stephan Ehl
BACKGROUND: Activated phosphoinositide-3-kinase δ syndrome (APDS) is an inborn error of immunity (IEI) with infection susceptibility and immune dysregulation, clinically overlapping with other conditions. Management depends on disease evolution, but predictors of severe disease are lacking. OBJECTIVES: This study sought to report the extended spectrum of disease manifestations in APDS1 versus APDS2; compare these to CTLA4 deficiency, NFKB1 deficiency, and STAT3 gain-of-function (GOF) disease; and identify predictors of severity in APDS...
June 28, 2023: Journal of Allergy and Clinical Immunology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
